Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials

Lenalidomide-RCHOP (R2-CHOP21) has been shown to be safe and effective in patients with untreated diffuse large B-cell lymphoma (DLBCL). The aim of this analysis is to report long-term outcome and toxicities in newly diagnosed DLBCL patients who received R2-CHOP21 in two independent phase 2 trials,...

Descripción completa

Detalles Bibliográficos
Autores principales: Castellino, A., Chiappella, A., LaPlant, B. R., Pederson, L. D., Gaidano, G., Macon, W. R., Inghirami, G., Reeder, C. B., Tucci, A., King, R. L., Congiu, A., Foran, J. M., Pavone, V., Rivera, C. E., Spina, M., Ansell, S. M., Cavallo, F., Molinari, A. L., Ciccone, Giovannino, Habermann, T. M., Witzig, T. E., Vitolo, U., Nowakowski, G. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224549/
https://www.ncbi.nlm.nih.gov/pubmed/30410035
http://dx.doi.org/10.1038/s41408-018-0145-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224549/
https://www.ncbi.nlm.nih.gov/pubmed/30410035
http://dx.doi.org/10.1038/s41408-018-0145-9

Ejemplares similares